AZN - Spark Newswire

1 minute read

FDA Accepts AstraZeneca’s sBLA for Imfinzi (durvalumab) in biliary tract cancer (BTC) with Priority Review

May 4, 9:11 AM

The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy and granted Priority Review for patients with locally advanced or metastatic biliary tract cancer (BTC).

AZN

2 minute read

FDA
News

AstraZeneca Announced Imfinzi Plus Chemotherapy Granted Priority Review in the Us for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial

By Charles Gross

May 4, 5:57 AM

AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer (BTC).

AZN

1 minute read

SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $75

By Benzinga Newsdesk

May 4, 4:43 AM

SVB Leerink analyst Andrew Berens maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $70 to $75.

AZN

1 minute read

Read Why This Analyst Is ‘Encouraged’ By Seagen’s Q1 Sales

By Vandana Singh

April 29, 3:40 PM

Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance.

AZN

1 minute read

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

By Vandana Singh

April 29, 6:10 AM

AstraZeneca Plc’s (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of…

AZN

3 minute read

A Peek Into The Markets: US Stock Futures Down; Apple Tops Q2 Views

By Lisa Levin

April 29, 5:49 AM

Pre-open movers

AAPL

4 minute read

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

By Vandana Singh

April 28, 8:52 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ABBV

1 minute read

Six US States Probing Mysterious Liver Inflammation In Kids: Bloomberg

By Vandana Singh

April 28, 7:28 AM

At least six U.S. states are reporting confirmed or suspected cases of an unexplained, severe liver disorder in children. Health officials in New York state and Wisconsin said they’re investigating reports of pediatric hepatitis that match a description released last week by the Centers for Disease Control and Prevention.

AZN

2 minute read

FDA
News

AstraZeneca Announced Ultomiris Approved in the US for Adults with gMG

By Charles Gross

April 28, 5:21 AM

Ultomiris (ravulizumab-cwvz) has been approved in the US for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease.1-5

AZN

4 minute read

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

By Vandana Singh

April 27, 8:45 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ACHV

Feed Symbols: AZN